Novo, a company that invests in life science companies, led a $100m Series C round in Asceneuron, a clinical stage biotech company developing small molecules targeting tau protein aggregation, with participation from EQT Life Sciences, M Ventures, Sofinnova Partners, GSK Equities Investments and Johnson & Johnson. "The financing will be used to advance Asceneuron’s lead asset ASN51 into Phase 2 clinical development for the treatment of Alzheimer’s disease. ASN51 is an oral small molecule drug designed to inhibit OGA, an enzyme implicated in protein aggregation. By preventing the aggregation of tau proteins, ASN51 aims to slow the progression of Alzheimer’s disease. OGA inhibition has also shown promising potential to prevent the aggregation of proteins that are central to other neurodegenerative diseases, including Parkinson’s disease and amyotrophic lateral sclerosis," Asceneuron.